EKNL – Running right though to Walmart’s show in April

New Post Public Reply Private Reply Replies (0) Message Board
xtremepicks

EKNL – Running right though to Walmart’s show in April 2013, New Alert Coming Soon!

EKNL, what a bargain and you bet insiders are looking to scoop up shares at every opportunity making the share float scarcer by the day. We already got confirmation that the share buyback is in full force with the announced 20% active float reduction. Smart investors loading up here at ridiculous low prices will be rewarded big time.

With the upcoming Walmart show in April, we definitely expect some significant updates leading up to this key conference. This is exactly why we will be running EKNL straight through to April.

We are also alerting our members that we will be dropping Fuse Science ( DROP ) and be replacing with a new XTREME alert very soon and to run along side our CORE pick, EKNL.

NEW ALERT COMING SOON!

Members who know our CORE plays , know that we feature and re-feature them for months – but the key here is to pick up super cheap shares at any opportunity and we will definitely be doing so with any weak traders selling EKNL for beer money.

This is exactly how many made HUGE gains with our other CORE play DROP and when sellers sold for peanuts missing out on the big gains – we were right in there buying and load up for XTREME gains.

Members holding on tight will definitely reap HUGE gains with $2 price target and 500% potential gains.

Key points that make EKNL an XTREME breakout play:

1) No dilution or insiders selling any time soon and especially at these super low prices.

2) Share buyback in effect . Definitely the reason here is to move prices up to proper valuations and big boards like Nasdaq requirements. We also got confirmation this is in full force with a 20% active float reduction, no doubt insiders looking to scoop much more.

3) Super Low float . With only 4.4 Million active float (shares available at the DTC for trading), EKNL ‘s share inventory is drying up super fast.

ABOUT EKO INTERNATIONAL

EKO International Corp. is a holding company focused on growth through acquisition. Each acquisition must have substantial growth potential and is expected to add assets and/or cash-flow to the consolidated financial statements of the Company. The Company  is willing to examine a variety of proposed target businesses and if interested, will negotiate terms and conditions of purchase favorable to itself.

Join our exclusive  Live CHAT on douknow.com by clicking here

Also, join us at our new investors hangout board at http://investorshangout.com/

Keep your eyes peeled for the latest updates on our twitter page , facebook page , and our website at http://www.xtremepicks.com .

Xtremepicks.com profiles are not a solicitation or recommendation to buy, sell or hold securities and is not offering securities for sale. Xtremepicks did not receive any compensation for the profile of EKNL, DROP and may be buyers in the open market Verify all claims and do your own due diligence. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Click here to view the full disclaimer

Eko International Cp (EKNL) Stock Research Links

EKNL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

BASIS Bellevue Expands with New K-4 Campus

Updated Category News Views 89

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

Continue Reading
Smirnoff Launches Marvel Event with $12.99 Offer

Updated Category News Views 68

Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...

Continue Reading
Ameritas Hires Actuarial Veteran as VP in Strategic Move

Updated Category News Views 115

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Continue Reading
Amgen Q3 2026 Results: What Investors Should Know

Updated Category News Views 93

Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...

Continue Reading
Royce Global Trust: Insights on RGT's Performance

Updated Category News Views 80

Analyzing Royce Global Trust's Approach When you dig into the Royce Global Trust portfolio, what emerges is a tapestry woven through decades of grit and determination in the investing world. This closed-end fund, trading under the symbol NYSE: RGT, is no stranger to the ebbs and flows of global markets. With every tick of the clock, speculation dances around this fund's...

Continue Reading
transcosmos: Not Just Calls—Evolving Business Strategy

Updated Category News Views 110

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Continue Reading
Bloomberg Law Awards Series Celebrates Legal Excellence

Updated Category News Views 54

New Awards Shine Light on Corporate Legal Teams Here's one for the books: Bloomberg Law is rolling out a shiny new awards program called Inside In-House: Legal Departments of the Year. Now, this isn't some vanity affair because it's aimed at celebrating the folks in legal teams who make companies tick behind the scenes. Openings for nominations run through November 20,...

Continue Reading
Oracle's Bold Vision: Targeting $225B Revenue by 2030

Updated Category News Views 132

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

Continue Reading
BD's New Liverty™ TIPS Stent: A Game Changer?

Updated Category News Views 75

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

Continue Reading
Ascletis' ASC30 Achieves Significant HbA1c Reductions

Updated Category News Views 73

When you dive into the world of biopharma, you never quite know what's going to grab your attention next. Today, it's Ascletis Pharma's (HKEX: 1672) GLP-1 receptor agonist, ASC30, that's piqued my interest. It just wrapped up a U.S. Phase II study with a bang, showing off with some impressive results for type 2 diabetes treatment. This ain't no half-hearted...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative AI Assistant by ClickBid Revolutionizes Fundraising

Updated Category News Views 155

ClickBid Introduces Groundbreaking AI Assistant ClickBid, recognized as a pioneer in event fundraising technology, proudly presents ClickBid Search. This is the first custom GPT-powered AI assistant tailored specifically for nonprofits, designed to offer immediate and relevant answers to help organizations optimize their event strategies. Available at no cost to all...

Continue Reading
TIER IV and TUM Drive Level 4 Autonomous Cars

Updated Category News Views 25

Autonomous Driving Gets a German Boost Well folks, looks like the autonomous vehicle scene is hitting the autobahns with more horsepower than ever before. Today’s chatter is all about how TIER IV and the Technical University of Munich (TUM) have teamed up, tapping into the grid as they ride the waves of cutting-edge NVIDIA tech. The Sparks Under the Hood: NVIDIA...

Continue Reading
Vericel Corporation's Upcoming Presentation at MedTech Conference

Updated Category News Views 147

Vericel Corporation's Engagement at the MedTech Conference CAMBRIDGE, Mass. — Vericel Corporation (NASDAQ:VCEL), a recognized leader in advanced therapies for sports medicine and severe burn care, has exciting news regarding its participation at the upcoming Truist Securities MedTech Conference. The company will be featured in a fireside chat, slated to take place at...

Continue Reading
Gildan Achieves Strong Q2 Results: Revenue and Finances Surge

Updated Category News Views 128

Gildan Reports Remarkable Growth in Second Quarter Earnings Gildan Activewear Inc. (NYSE: GIL, TSX: GIL) has achieved record net sales of $919 million during the second quarter, reflecting a strong 6.5% increase compared to the previous year. Strong Operational Performance and Profitability This quarter's operating margin stood at an impressive 21.7%, with an adjusted...

Continue Reading
MimiVax and UI Pharmaceuticals Mark Key Production Milestone

Updated Category News Views 260

MimiVax and UI Pharmaceuticals Mark Key Production Milestone MimiVax and UI Pharmaceuticals have achieved an exciting development in the field of cancer treatment with the clinical manufacture of SurVaxM, an innovative immunotherapeutic vaccine aimed at targeting glioblastoma. SurVaxM proudly stands out as the first product to be manufactured at UI Pharmaceuticals' newly...

Continue Reading